Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 15/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSC | P53634 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27101806 | 1.00 | EPHX2 (0.65) | EPHX2EPHX1CTSLCTSBCTSS | |
| SCHEMBL26554653 | 0.82 | CA12 (0.61) | EPHX2EPHX1USP30 | |
| SCHEMBL27100904 | 0.81 | CYP1A2 (0.57) | CTSLCTSBCTSSCTSCUSP30 | |
| SCHEMBL25403939 | 0.81 | CYP1A2 (0.57) | CTSLCTSBCTSSCTSCUSP30 | |
| SCHEMBL25400740 | 0.81 | CYP1A2 (0.57) | CTSLCTSBCTSSCTSCUSP30 | |
| SCHEMBL18307140 | 0.79 | EPHX1 (0.84) | EPHX2EPHX1DPP4KCNH2DPP7 | |
| SCHEMBL2728845 | 0.79 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL23390333 | 0.78 | PTPN1 (0.52) | EPHX2 | |
| SCHEMBL3960592 | 0.78 | EPHX2 (0.72) | EPHX2EPHX1 | |
| SCHEMBL27577307 | 0.78 | EPHX2 (0.72) | EPHX2EPHX1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-4211111-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | University of Virginia Patent Foundation (US) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | EPHX2 1688/4885EPHX1 3679/4885CTSL 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.